<Study> UBS Ratings and Target Prices for Chinese Pharmaceuticals (Table)

Written by Emily J. Thompson, Senior Investment Analyst

01093-0.1%

01177-1.55%

01276-1.39%

Source: aastocks

Updated: Sep 30 2025

0mins

Source: aastocks

Stock Performance Overview: Several pharmaceutical stocks showed mixed performance, with HENGRUI PHARMA and HANSOH PHARMA experiencing gains, while CSPC PHARMA and KELUN PHARM saw slight declines.
Short Selling Data: Short selling activity was notable, particularly for CSPC PHARMA and SIMCERE PHARMA, with significant ratios indicating investor caution in these stocks.

01093

$9.8+Infinity%1D

Analyst Views on 01093

Wall Street analysts forecast 01093 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01093 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Analyst Rating

0 Buy

0 Hold

0 Sell

Current: 9.810

Low

Averages

High

Current: 9.810

Low

Averages

High

Daiwa

Buy

Hold

downgrade

$100 -> $116

Al Analysis

2026-01-05

Reason

Daiwa

Price Target

$100 -> $116

Al Analysis

2026-01-05

downgrade

Buy

Hold

Reason

The analyst rating from Daiwa reflects a more cautious approach for 2026, recommending a selective strategy focused on quality stocks after a strong performance in the Chinese biopharmaceutical sector in 2025. The downgrade of AKESO from Buy to Hold is attributed to a lack of short-term catalysts, despite an increase in its target price. Conversely, Daiwa has raised the target price for INNOVENT BIO, indicating confidence in its potential, while maintaining a Sell rating for CSPC PHARMA, suggesting a negative outlook for that stock.

BofA Securities

Buy

maintain

$45

2025-12-24

Reason

BofA Securities

Price Target

$45

2025-12-24

maintain

Buy

Reason

The analyst rating for HANSOH PHARMA was maintained at "Buy" due to the company achieving the highest year-over-year sales growth among its peers at 8.6% in October, with most of its key products recording double-digit month-over-month growth. In contrast, HENGRUI PHARMA received an "Underperform" rating because several of its key products faced pressure, despite a 2% year-over-year increase in total sample sales. SINO BIOPHARM was also rated "Buy" due to the significant licensing potential of its pipeline products, despite a reduction in sales forecasts for some products. CSPC PHARMA was rated "Underperform" due to sluggish sales performance in October.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for 01093

Unlock Now

Morgan Stanley

Overweight

downgrade

$11

2025-12-17

Reason

Morgan Stanley

Price Target

$11

2025-12-17

downgrade

Overweight

Reason

The analyst rating for CSPC PHARMA was updated to "Overweight" by Morgan Stanley due to a revision in the company's sales forecasts for 2025-26, which were cut by 1% and 2%, respectively. Despite these reductions, the 2027 sales forecast remained unchanged. Additionally, estimates for recurring net profit were lowered by 4% for 2025-26, while the 2027 estimate stayed the same. The target price was also decreased from HKD11 to HKD10.4, reflecting the adjustments made based on the company's 3Q25 results and management guidance.

Daiwa

downgrade

$17.4

2025-10-27

Reason

Daiwa

Price Target

$17.4

2025-10-27

downgrade

Reason

The analyst rating from CLSA reflects a cautious yet optimistic outlook on China's biotechnology and innovative drug industry. The reasons for the ratings include: 1. Market Volatility and Overvaluation: The industry has faced volatility due to overvaluation from previous price hikes and uncertainty regarding national medical insurance drug pricing. 2. Attractive Valuations: Despite the volatility, CLSA notes that valuations of quality companies are becoming attractive, suggesting potential for investment. 3. Ongoing Business Expansion: There are ongoing business expansion activities, which could lead to future growth opportunities. 4. Limited Downside Risk: CLSA believes that further downside price risk seems limited, indicating a more stable outlook moving forward. 5. Healthy Consolidation: The current pullback in stock prices is viewed as a healthy consolidation phase, providing attractive opportunities for investment in the coming year. 6. Specific Company Insights: For CSPC PHARMA, despite delays in business expansion affecting investor confidence, CLSA sees this as creating more attractive buying opportunities. For SINOPHARM, improvements in accounts receivable and the initiation of China's 15th Five-Year Plan are expected to support recovery in earnings momentum. Overall, the ratings reflect a belief in the potential for recovery and growth in the sector, despite current challenges.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

<Study> UBS Ratings and Target Prices for Chinese Pharmaceuticals (Table)

Analyst Views on 01093

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

J.B. Hunt Reports Q4 EPS of $1.90, Revenue Misses Expectations

UBS Bullish on North American Containerboard Sector, Forecasts $40 Price Increase in 2026

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch